Observation 1:

The firm failed to validate disinfectant and sanitization procedures used in the clean controlled manufacturing areas and did not ensure that product quality is not compromised.

For example,

A. The firm has fumigated the Plant [0(4)], the clean controlled Powder Processing Areas, [0(4)] times in 2014, 2015, and 2016 with [0(4)] disinfectant solution according to SOP AMP-044-02, titled "Fumigation in Powder Processing Area", effective date 6/25/2016, after microbiological environmental monitoring alert levels were exceeded. The Powder Processing Areas are used in finished API production, for example for [0(4)] and [0(4)] USP. When fumigation is to be done, the [0(4)] solution is aerosolized to cover the entire area of a room. The firm removes equipment and product stored in the room prior to fumigation, but when product in [0(4)] drums cannot be removed from the room, the procedure states the drums "shall be covered properly as to avoid cross contamination."

The firm did not do the following prior to implementing the fumigation procedure:

• Validate the sanitization to ensure that the method used to cover the product drums prevents contamination of the product from the fumigation agents.
• Establish that product quality is not impacted from the fumigation.
• Record in the fumigation logs which product in drums were left in the rooms.
B. The following disinfectant and sanitization protocols and reports, used in the clean controlled Powder Processing Areas where products such as \( (8)(4) \) and \( (6)(4) \) USP are produced. These protocols were prepared at \( (8)(4) \) sites, such as at the \( (8)(4) \) and \( (6)(4) \) sites, and were used without validation at the Dabhasa site:

- Disinfectant Validation Protocol, VAP/DIS/VAL/08/15, effective 8/13/15 for the use of disinfectants such as \( (8)(4) \); completed at the \( (8)(4) \) site.
- Disinfectant Validation Report, VAP/DIS/VAL/08/15, effective 9/25/15, for the use of \( (8)(4) \); completed at the \( (8)(4) \) site.
- Validation protocol, titled "Evaluation of Efficacy of Sanitizing Agent (in vivo studies)", AMV/10/79/00, effective 3/31/08, for the use of sanitizing agents such as \( (8)(4) \) completed at the \( (8)(4) \) site.
- Validation report, titled "Evaluation of Efficacy of Sanitizing Agent (in vivo studies)", AMV/10/79/00, effective 7/29/08, for the use of sanitizing agents such as \( (8)(4) \) completed at the \( (8)(4) \) site.

Observation 2:

The firm failed to perform specific identification tests on the vendor supplied \( (8)(4) \) that is used to create an \( (8)(4) \) for the bulk packaging of APIs.

Specifically, your firm's receipt of the \( (8)(4) \) material, used in the \( (8)(4) \) of your firm's \( (8)(4) \) drug substance packaging was accepted for use with supplier provided COA for the raw material, in lieu of testing of the raw material for conformity with all appropriate written specifications, without performing at least one specific identity test on the raw material and establishing the reliability of the supplier's analyses through appropriate validation of the supplier's test results at appropriate intervals.